To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy

Summary

N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development of diabetic microvascular complications through the promotion of retinal angiogenesis and increased vascular permeability. It was reported in the literature that NAC administration was safe in several studies. It was shown that the dose of 1200 mg is safe and effective. To the best of our knowledge, the present study is the first to be designed to evaluate the effect of N-acetyl cysteine on diabetic retinopathy in type 2 diabetic patients.

Eligibility

Inclusion Criteria:

* Patients with type 2 diabetes mellitus

  * Patients with mild to moderate degrees of diabetic retinopathy
  * Patients over the age of 18 and under the age of 70 years
  * Patients who voluntarily give their informed consent
  * HbA1C (glycosylated hemoglobin) less than 10%
  * FBG less than 240 mg/dl
  * Body mass index (BMI) less than 40 kg/m2

Exclusion Criteria:

* • Patients with any other ophthalmologic conditions than diabetic retinopathy

  * Patients with previous surgical or laser treatment
  * Pregnant or breastfeeding patients
  * Patients using antioxidants.
  * Systemic anti-VEGF or pro-VEGF treatment within 4 months before randomization
  * Patients who are currently participating in other clinical trials
  * Severe liver or renal disease, (AST or ALT \>3 times ULN or Total bilirubin \>3 times ULN), (CrCl\< 60 ml/min)
  * Current history of drug or alcohol abuse Malignancies

Conditions2

Interventions1

Browse More Trials